Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  ramucirumab
Find trials that include:  Any drugs shown
Results 1-19 of 19 for your search:
Start Over
A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Participants With EGFR Mutation-Positive Metastatic NSCLC
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 15540, NCI-2016-00365, 2014-004824-22, I4T-MC-JVCY, NCT02411448
A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15679, NCI-2015-02085, 2014-003655-66, I4T-MC-JVDC, NCT02426125
A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15755, NCI-2016-00158, 2014-005068-13, I4T-MC-JVDE, NCT02435433
A Study of LY2875358 in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15246, NCI-2014-02649, I4C-MC-JTBF, NCT02082210
Irinotecan Hydrochloride and Cetuximab with or without Ramucirumab in Treating Patients with Advanced Colorectal Cancer with Progressive Disease after Treatment with Bevacizumab-Containing Chemotherapy
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: E7208, NCI-2011-02018, CDR0000666736, ECOG-E7208, NCT01079780
A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15608, NCI-2015-01087, 2014-003791-23, I4T-MC-JVDB, NCT02443883
Ramucirumab in Treating Patients with Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2015-0393, NCI-2015-01442, NCT02520141
A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 15541, NCI-2016-00243, 2014-005067-32, I4T-MC-JVCZ, NCT02514551
Combination Chemotherapy with or without Ramucirumab in Treating Patients with Metastatic or Recurrent Pancreatic Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: HCRNGI14-198, NCI-2016-00206, IRB00086601, Winship3142-16, NCT02581215
Ramucirumab, Trastuzumab, Capecitabine, and Cisplatin in Treating Patients with Stage IV HER2-Positive Gastroesophageal Junction or Gastric Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-301, NCI-2016-00548, NCT02726399
Ramucirumab and Somatostatin Analog Therapy in Treating Patients with Locally Advanced or Metastatic Carcinoid Tumor That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 16-072, NCI-2016-00941, NCT02795858
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 16329, NCI-2016-01171, 2015-004699-31, I3O-MC-JSBF, NCT02711553
Ramucirumab and Nab-Paclitaxel in Treating Patients with Previously Treated Stage IV Non-small Cell Lung Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: UPCI 15-169, NCI-2016-01641, NCT02730247
A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC)
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15266, NCI-2014-00892, 2013-004648-41, I3Y-MC-JPBJ, KEYNOTE-238, NCT02079636
A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15787, NCI-2015-01802, 2015-001473-40, I4T-MC-JVDF, KEYNOTE -098, NCT02443324
Ramucirumab in Treating Younger Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 21
Trial IDs: ADVL1416, NCI-2015-00744, NCT02564198
A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 16116, NCI-2015-02279, 2015-003013-14, I4T-MC-JVDJ, NCT02572687
A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 16088, NCI-2016-01008, 2016-000440-33, I8J-MC-JYCA, NCT02791334
International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer
Status: Active
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: 14945, NCI-2014-00991, I4T-MC-JVCP, NCT02065765
Start Over